Literature DB >> 26834845

Osteoporosis therapeutics: recent developments at ASBMR.

Gordon Mallarkey1, David M Reid2.   

Abstract

Entities:  

Year:  2016        PMID： 26834845      PMCID： PMC4707418          DOI： 10.1177/1759720X15623489

Source DB:  PubMed          Journal:  Ther Adv Musculoskelet Dis        ISSN： 1759-720X            Impact factor:   5.346


× No keyword cloud information.
  6 in total

1.  Romosozumab in postmenopausal women with low bone mineral density.

Authors:  Michael R McClung; Andreas Grauer; Steven Boonen; Michael A Bolognese; Jacques P Brown; Adolfo Diez-Perez; Bente L Langdahl; Jean-Yves Reginster; Jose R Zanchetta; Scott M Wasserman; Leonid Katz; Judy Maddox; Yu-Ching Yang; Cesar Libanati; Henry G Bone
Journal:  N Engl J Med       Date:  2014-01-01       Impact factor: 91.245

2.  Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT Study.

Authors:  Joy N Tsai; Alexander V Uihlein; Sherri-Ann M Burnett-Bowie; Robert M Neer; Yuli Zhu; Nicholas Derrico; Hang Lee; Mary L Bouxsein; Benjamin Z Leder
Journal:  J Bone Miner Res       Date:  2015-01       Impact factor: 6.741

3.  Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.

Authors:  Joy N Tsai; Alexander V Uihlein; Hang Lee; Ruchit Kumbhani; Erica Siwila-Sackman; Elizabeth A McKay; Sherri-Ann M Burnett-Bowie; Robert M Neer; Benjamin Z Leder
Journal:  Lancet       Date:  2013-05-15       Impact factor: 79.321

4.  Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.

Authors:  Benjamin Z Leder; Joy N Tsai; Alexander V Uihlein; Sherri-Ann M Burnett-Bowie; Yuli Zhu; Katelyn Foley; Hang Lee; Robert M Neer
Journal:  J Clin Endocrinol Metab       Date:  2014-02-11       Impact factor: 5.958

5.  The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.

Authors:  S Papapoulos; K Lippuner; C Roux; C J F Lin; D L Kendler; E M Lewiecki; M L Brandi; E Czerwiński; E Franek; P Lakatos; C Mautalen; S Minisola; J Y Reginster; S Jensen; N S Daizadeh; A Wang; M Gavin; C Libanati; R B Wagman; H G Bone
Journal:  Osteoporos Int       Date:  2015-07-23       Impact factor: 4.507

6.  Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.

Authors:  H G Bone; D W Dempster; J A Eisman; S L Greenspan; M R McClung; T Nakamura; S Papapoulos; W J Shih; A Rybak-Feiglin; A C Santora; N Verbruggen; A T Leung; A Lombardi
Journal:  Osteoporos Int       Date:  2014-11-29       Impact factor: 4.507
  6 in total
  1 in total

Review 1.  Management of adynamic bone disease in chronic kidney disease: A brief review.

Authors:  Swathi K Sista; Seth M Arum
Journal:  J Clin Transl Endocrinol       Date:  2016-07-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.